Search Results 161-170 of 16622 for fibrosis quistica
TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor- ...
The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis. Participation eligibility.
The purpose of this study is to evaluate an ultrasound technology that may be used to evaluate liver fibrosis. Participation eligibility. Participant ...
Secondary FSGS . Several factors, such as infection, drug toxicity, diseases including diabetes or sickle cell disease, obesity, and even other kidney diseases ...
This genetic condition causes tumors on nerve tissue. Surgery and other therapies can manage symptoms.
Clinical Trials · A Study to Evaluate the Effectiveness and Safety of Pamrevlumab in Patients with Idiopathic Pulmonary Fibrosis · More about research at Mayo ...
... Fibrosis (IPF). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...
A Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in Idiopathic Pulmonary Fibrosis (IPF) · Overview · Participation eligibility · Participating ...
Teng Moua, M.D., discusses recent clinical trials and current research into the treatment of idiopathic pulmonary fibrosis (IPF) and non-IPF-progressive ...
Fibrosing mediastinitis (FM) represents a fibroinflammatory disease involving the mediastinum and hilar areas. It is characterized by expansive growth of ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Make a gift before July 31 and it can be doubled in impact thanks to a $100,000 Summer Challenge.